首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNTF |
| Uniprot No | P26441 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-200aa |
| 氨基酸序列 | AFTEHSPLTPHRRDLCSRSIWLARKIRSDLTALTESYVKHQGLNKNINLD SADGMPVASTDQWSELTEAERLQENLQAYRTFHVLLARLLEDQQVHFTPT EGDFHQAIHTLLLQVAAFAYQIEELMILLEYKIPRNEADGMPINVGDGGL FEKKLWGLKVLQELSQWTVRSIHDLRFISSHQTGIPARGSHYIANNKKM |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于CNTF重组蛋白的参考文献及摘要概括：
1. **文献名称**：*"Recombinant human ciliary neurotrophic factor (rhCNTF) delays motor function impairment in a transgenic model of familial amyotrophic lateral sclerosis"*
**作者**：Davis et al.
**摘要**：研究通过转基因ALS小鼠模型，发现重组人CNTF蛋白能延缓运动神经元退化和肌肉功能丧失，表明其在神经退行性疾病中的潜在治疗价值。
2. **文献名称**：*"CNTF promotes the survival of retinal ganglion cells after optic nerve injury"*
**作者**：LaVail et al.
**摘要**：实验表明，玻璃体内注射重组CNTF蛋白可显著提高大鼠视神经损伤后视网膜神经节细胞的存活率，提示其在眼科疾病治疗中的应用前景。
3. **文献名称**：*"Metabolic effects of recombinant human CNTF in humans with type 2 diabetes"*
**作者**：Ettinger et al.
**摘要**：临床试验发现，重组CNTF可通过激活JAK-STAT通路改善2型糖尿病患者的胰岛素敏感性，但伴随体重下降等副作用，需进一步优化给药策略。
4. **文献名称**：*"Nanoparticle-mediated delivery of CNTF enhances neuronal regeneration in a rodent model of spinal cord injury"*
**作者**：Zhang et al.
**摘要**：开发了一种基于纳米颗粒的重组CNTF递送系统，在脊髓损伤模型中显著促进轴突再生和功能恢复，验证了新型载药系统对CNTF疗效的提升。
(注：以上文献信息为模拟示例，实际引用需核对真实数据库及原文。)
Ciliary Neurotrophic Factor (CNTF) is a secreted cytokine initially identified for its role in supporting the survival of neuronal populations, particularly motor neurons, in the peripheral and central nervous systems. Discovered in the early 1990s, CNTF is primarily expressed in glial cells, including astrocytes and Schwann cells, and signals through a tripartite receptor complex involving CNTFRα, gp130. and LIFRβ. Structurally, it belongs to the interleukin-6 (IL-6) cytokine family and shares a characteristic four-helix bundle motif. Unlike typical cytokines, CNTF lacks a signal peptide and is released passively upon cellular injury, acting as a "damage signal" to promote neuroprotection and regeneration.
Research on recombinant CNTF (rhCNTF) gained momentum due to its therapeutic potential in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and retinal degeneration. Preclinical studies demonstrated its ability to delay motor neuron loss and enhance axonal regeneration. However, clinical trials in ALS showed limited efficacy and significant side effects, including weight loss and inflammation, leading to discontinuation of its development for this indication. Intriguingly, CNTF's metabolic effects, including appetite suppression and insulin sensitivity modulation, sparked interest in obesity and diabetes research. Recombinant CNTF variants with improved safety profiles are now being explored.
Produced via bacterial or mammalian expression systems, rhCNTF retains bioactivity and is used extensively in mechanistic studies and drug development. Its dual role as a neurotrophic and metabolic regulator continues to make it a compelling subject for translational research.
×
